The human bone marrow (hBM) is a complex organ critical for hematopoietic and immune 22 homeostasis, and where many cancers metastasize. Yet, understanding the fundamental biology of 23 the hBM in health and diseases remain difficult due to complexity of studying or manipulating the 24 BM in humans. Accurate in vitro models of the hBM microenvironment are critical to further our 25 understanding of the BM niche and advancing new clinical interventions. Although, in vitro 26 culture models that recapitulate some key components of the BM niche have been reported, there 27 are no examples of a fully human, in vitro, organoid platform that incorporates the various niches 28 of the hBM -specifically the endosteal, central marrow, and perivascular niches -thus limiting 29 their physiological relevance. Here we report an hBM-on-a-chip that incorporates these three 30 niches in a single micro-physiological device. Osteogenic differentiation of hMSCs produced 31 robust mineralization on the PDMS surface ("bone layer") and subsequent seeding of endothelial 32 cells and hMSCs in a hydrogel network ("central marrow") created an interconnected vascular 33 network ("perivascular niche") on top. We show that this multi-niche hBM accurately mimics the 34 ECM composition, allows hematopoietic progenitor cell proliferation and migration, and is 35 affected by radiation. A key finding is that the endosteal niche significantly contributes to hBM 36 physiology. Taken together, this multi-niche micro-physiological system opens up new 37 opportunities in hBM research and therapeutics development, and can be used to better understand 38 hBM physiology, normal and impaired hematopoiesis, and hBM pathologies, including cancer 39 metastasis, multiple myelomas, and BM failures. 40 41 42
Introduction osteopontin (OPN)). OBs also provide soluble and surface bound signals, like jagged-1 (JAG1) 66 and stem cell factor (SCF), to HSCs and HPCs that regulate differentiation and potency. The 67 endosteal niche was believed to be relatively hypoxic and this was thought to promote HSC 68 maintenance of potency; however, recent studies have not found the endosteal niche to be hypoxic 69 (15). In part, this is due to the high vascularization throughout the bone compartment. BM 70 sinusoids permeate the bone cavity and serve as the connection between BM and peripheral 71 tissues, allowing for the egress of progenitors of the hematopoietic system. Endothelial cells (ECs) 72 comprise the BM sinusoids and are accompanied by mesenchymal stromal cells (MSCs) or 73 pericytes in establishing the perivascular niche. Abundant levels of stromal derived factor 1 (SDF1 74 or CXCL12) and SCF are expressed in the perivascular space to establish the HSC niche and 75 recent in vivo studies have observed HSCs to be resident in the perivascular niche (16) (17) (18) . 76
The HSC niche has been a subject of study for decades and there have been many efforts to 77 recapitulate aspects of the niche in vitro. Various material approaches and simple co-culture 78 platforms in both 2D and 3D have been reported to increase HSC proliferation or maintain HSC 79 potency during in vitro culture (19-21). Culture systems have been developed that mimic specific 80 cytokine (22) or ECM (23) environments that HSCs experience in the BM niche in vivo. More 81 recently, ex vivo and in vitro microfluidic or on-chip devices have been designed for recreating the 82 bone or BM microenvironment (24-26). These studies recapitulate many characteristics of bone 83 marrow; however, they either require lengthy ectopic implantation in animal models, or do not 84 recreate the vasculature of BM, or do not incorporate the multiple juxtaposed niches of the BM 85 microenvironment (especially the endosteal niche with the central marrow an dperivascular niche 86 together), and ultimately are neither fully human nor complete models of the hBM. 87
Here, we present a simple microfluidic human BM-on-a-chip (hBM-on-a-chip) that can be used to 88 create a human MSC-derived endosteal surface overlaid with a microvascular hydrogel network 89 with hMSCs representing the central marrow and perivascular niches -that mimic the basic multi-90 niche structure of the human BM ( Fig. 1B) . We demonstrate the use of this device to study HSC 91 response to a variety of stimuli, such as radiation and clinical HSC mobilization agents. This 92 device can also be used to study human BM physiology and pathologies, including cancer 93 metastasis, multiple myelomas, and bone marrow failures. To further improve on the design and standardization of hBM-on-a-chip, a microfluidic platform 141 was developed to integrate the platform into a standard, well-plate format. Using previously 142 published methods (29-31), the PDMS "device" layer was bonded directly to a commercially 143 available, bottomless 96-well plate (Error! Reference source not found.H, I). The resulting array 144 of 8 devices uses the wells of the plate as media reservoirs and as a window for imaging the 145 central channel of the device (Error! Reference source not found.J, K). This process creates an 146 array of devices that are consistently oriented within known well locations, making the platform 147 easily transferable to automated imaging, or potentially, media handling instrumentation. An 148 unexpected benefit of moving to this fabrication method was the increased "survival" of devices 149 during the 21-day differentiation of MSCs. This was most likely because the PDMS portion of the 150 construct is fixed to a rigid polystyrene frame, so there were no longer small deformations due to 151 handling of the devices during loading and culture, resulting in a much lower frequency, less than 152 5%, of device "failure" (Error! Reference source not found.C). 153
On-Chip Osteogenic differentiation of hMSCs Create Mineralized Endosteal Niche 154
To promote cell adhesion to the bottom surface of PDMS within the central channel of the device, 155 microfluidic devices were coated with polydopamine (PDA) and collagen I(32), which was found 156 to improve attachment of hMSCs when compared to collagen I or fibronectin alone (Error! 157 Reference source not found.A). hMSCs were then seeded at a high density within the central 158 channel of the device and differentiated with osteogenic media over a period of 21 days. 159
Mineralization of matrix was observed by Alizarin red ( Fig. 2A 
Generation of the Central Marrow and Perivascular Niche on the Endosteal Niche 177
In recent years, several groups have published methods for in vitro vasculogenesis in similar 178 microfluidic platforms (27, 28, 33, 34) . We found that perfusion of the vasculature was most 179 consistent using a combination of hMSCs in laterally adjacent channels, supplementation with 180 vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG-1), and encapsulation of 181 endothelial cells in a fibrin/collagen co-gel (Error! Reference source not found.). Seeding 182
HUVECs and hMSCs on top of the newly formed endosteal surface and culturing under these 183 conditions for 5 days created vasculature in a reproducible manner. 184
Effect of stromal cells on vasculogenesis 185
hBM-on-a-chip microfluidic devices were created with and without hMSCs and the differentiated 186 endosteal layer (OBs) to measure the effect of stromal cells on vasculogenesis and cytokine 187 secretion ( Fig. 3A ). We observed no significant difference in the vasculature area containing 
Effect of stromal cells on cytokine secretion 209
We observed differences in cytokine expression as function of stromal cell inclusion using 210 multiplex cytokine detection to analyze the supernatant collected from the devices on day 5 of 211 vasculogenesis ( Fig. 3D ). OB containing devices, in general, secreted higher amounts of 212 cytokines. IL-6, a cytokine involved in B cell differentiation, was highly expressed in EC+OB 213 (624±212 pg/mL) and EC+MSC+OB (386±49 pg/mL) samples, less was measured to be present in 214 EC (162±49 pg/mL) and EC+MSC (132±34 pg/mL). IL-11, which is responsible for signaling 215 during megakaryocyte maturation, was measure in trace concentrations in EC (4.1±1.8 pg/mL) 216
devices and not at all in EC+MSC samples, while substantial concentrations were observed in 217 EC+OB (308±73 pg/mL) and EC+MSC+OB (254±64 pg/mL) devices. Similarly, M-CSF, which 218 induces macrophage differentiation of HSCs, was elevated in EC+OB (58.3±5.3 pg/mL) and 219 EC+MSC+OB (68.6±2.1 pg/mL) devices, while little was detected in EC (15.2±7.6 pg/mL) and 220 EC+MSC (10.3±3.5 pg/mL) devices. Relatively small concentrations of IL-7 (lymphoid 221 progenitors), IL-34 (monocytes and macrophages), GM-CSF (granulocytes and macrophages), 222
FLT-3L (dendritic cells), and SCF (HSC maintenance) were measured and there was no significant 223 difference across groups. For both CXCL12 (hematopoietic chemoattractant) and IL-3 (myeloid 224 progenitors), no measurable analytes were detected. 225
Characterization of cytokine and ECM expression on the hBM-on-a-chip 226
After 5 days of vasculogenesis, hBM-on-a-chip containing the endosteal layer and subsequently 227 seeded hMSCs and HUVECs were fixed and stained to characterize the presence and localization 228 of cytokines and ECM relevant to the BM niche ( Fig. 3E-G ). CXCL12 and SCF were both found 229 to be expressed by perivascular and endothelial cells. Fibronectin was observed to be present in the 230 "central marrow" space outside of the newly formed vasculature. This arrangement of cytokine 231 expression is consistent with the distribution that has been seen in vivo. 232
HSPCs in hBM-on-a-chip 233
We next sought to investigate the inclusion of BM HSPCs in the hBM-on-a-chip and how MSCs 234
and OBs affected their fate in our BM model. BM CD34+ cells were briefly expanded in vitro out 235 of cryo-storage and then loaded into the central channel with HUVECs and MSCs. We measured 236 the expansion of the HSPCs via microscopy over the 5 days of culture during vasculogenesis (Fig. 237 4A and Error! Reference source not found.A). On day 1, the number of HSPCs in hBM-on-a-238 chip was not significantly different in MSC and/or OB containing devices. By day 3 and 239 continuing to day 5, devices without OBs had significantly more HSPCs than devices with the 240 endosteal layer. HSPCs culture with ECs and MSCs expanded 2.41-and 2.28-fold, respectively, 241 over 5 days, whereas both groups with HSPCs cultured in the presence of the pre-formed endosteal 242 layer only expanded 1.83-fold ( Fig. 4Aii) . 243
HSPCs will rapidly differentiate when cultured in vitro. We attempted to measure the effect of 244
MSCs and OBs on the differentiation of HSPCs in the hBM-on-a-chip by staining for CD34 ( Fig comparisons test. EC vs EC+OB p = 0.0813; EC vs EC+MSC+OB p = 0.0162. (B) Quantification 254 of immunofluorescence of HSPCs cultured for 5 days in hBM-on-a-chip with ECs only (black), 255
with MSCs (red), OBs (blue), and both (green). (i) Aggregate MFI of CD34. Data are shown with 256 median, quartiles, min and max (n = 452 cells for isotype from 1 device, n = 800 cells for EC, n = 257 907 cells EC+MSC, n = 945 cells EC+OB, n = 799 cells EC+MSC+OB pooled from 3 devices). 258
(ii) Percentage of CD34 + cells. Data are shown as mean ± SEM (n = 3 devices). Grey line is 259 percentage of CD34 + cells in isotype sample using gating scheme. 260
Mobilization of CD34+ HSPCs in hBM-on-a-chip 261
In order to measure the mobilization of HSPCs in hBM-on-a-chip, we designed an experimental 262 assay where devices were imaged every 2 hours over a 24-hour period after treatment with 263 mobilizing agents (Error! Reference source not found.). During each imaging session, devices 264 were imaged 4 times in 5-minute intervals and these images were used to track cell movement and 265 measure the length and displacement at discrete points in time during the 24-hour period. OBs (solid lines) were treated with 10 ng/mL G-CSF (light blue) or were untreated (black) and 290 movement of HSPCs was measured over 24-hours. Data are shown as mean of geometric means ± 291 SEM (n = 3 devices +OB untreated, n = 5 devices -OB untreated, n = 6 devices -OB and +OB 10 292 ng/mL G-CSF). 293 294
Radiation of CD34+ HSPCs in hBM-on-a-chip 295
To investigate the effect of ionizing radiation on the BM microenvironment in hBM-on-a-chip, 296
after 5 days of vasculogenesis, devices containing OBs, MSCs, and ECs were exposed to 0 Gy, 2.5 297 Gy, 5 Gy, or 10 Gy X-ray irradiation. Device supernatant was collected at 0 hours (pre-treatment) 298
and 24 hours radiation exposure. To measure cytotoxicity because of radiation, the change in 299 lactate dehydrogenase (LDH) activity of the supernatant after irradiation was measured (Error! 300 Reference source not found.C). Although we did not measure a significant increase in LDH 301 activity, the LDH activity in devices exposed to 5 Gy and 10 Gy X-ray radiation marginally 302 increased after exposure, while the activity in devices exposed to 0 Gy and 2.5 Gy radiation 303 slightly decreased during the same period. 304
The change in cytokine secretion because of X-ray exposure was also measured. IL-6, IL-7, IL-11, 305 M-CSF, and SCF were detected, however CXCL12, IL-3, IL-15, IL-34, GM-CSF, FLT3L, and 306 LIF were not above the detection limit of the assay. While there was no significant difference 307 between the groups, it is worth noting that there was a decrease in secretion of IL-6, IL-7, IL-11, 308 M-CSF, and SCF for all irradiated groups (Error! Reference source not found.D). 309
We sought to determine whether the presence of the endosteal niche was ameliorating the effects 310 of radiation for HSPCs. hBM-on-a-chip with (EC+MSC+OB+HSPC) and without 311 (EC+MSC+HSPC) the endosteal niche, were exposed to 5 Gy X-ray radiation and again apoptosis 312 was measured 24 hours after exposure via a TUNEL assay (Fig. 6) . Similarly, high backgrounds of 313 apoptotic HSPCs were observed, 17.5 ± 0.1% of HSPCs in untreated -OB samples and 16.3 ± 314 2.8% of HSPCs in untreated +OB samples staining positive for TUNEL ( Fig. 6B ). While there 315
was not a statistically significant difference between any of the groups, we observed a moderate 316 increase in TUNEL + HSPCs in +OB devices exposed to 5 Gy radiation (17.7 ± 2.0%). There was a 317 larger increase in TUNEL + HSPCs when exposed to 5 Gy radiation without the endosteal niche (-318 OB) present, with 22.6 ± 1.9% of HSPCs apoptotic. images of TUNEL (white) and CD45 (green) staining of devices, with or without OBs, exposed to 322 0 or 5 Gy radiation 24 hours after exposure. Scale bar: 50 µm. (B) Quantification of percentage of 323 TUNEL + CD45 cells, with (triangles) or without (circles) OBs, 24 hours after 0 (white) or 5 (grey) 324
Gy. Data are shown as mean ± SEM (n = 3 devices). Data analyzed using Kruskal-Wallis with 325
Dunn's multiple comparisons test. No significance between groups (p < 0.1). 326
Discussion

328
We have developed a simple model of the hBM microenvironment that incorporates both the 329 endosteal and perivascular niches and demonstrated that this approach for an hBM-on-a-chip 330 generates basic cytokine and ECM expression characteristic of BM that has been observed in vivo. 331
Additionally, we have shown that the inclusion of the endosteal layer and perivascular hMSCs 332 impacts the proliferation and fate of HSPCs co-cultured within the device. Due to the limited 333 volume of the current design, this model is not an appropriate approach for the ex vivo expansion 334 of hematopoietic cells for eventual transplantation, however we believe the hBM-on-a-chip could 335 be a useful tool for studying HSPC or other therapeutic cell interactions with specific BM 336 microenvironments and the constituent stromal and hematopoietic cells. Inclusion of additional 337 cell types, such as macrophages, osteoclasts, adipocytes, could easily be achieved and introduce 338 additional nuance and complexity to this model. These studies could expand beyond normal 339 conditions and the hBM-on-a-chip could be used as a platform for studying the effects of cancer, 340 radiation, or other perturbed states, and for the screening of therapeutics that target BM resident 341 cells to elicit a therapeutic response, such as mobilization. 342
The mobilization of HSPCs from the BM niche into peripheral blood for collection by apheresis is 343 a critical process for in both autologous and allogeneic HSC transplantation (35). G-CSF has long 344 been used in conjunction chemotherapy (typically cyclophosphamide) to mobilize BM HSPCs, 345 however it is not effective in all patients. Previous chemotherapy or radiotherapy regimens, age, 346 and disease burden are potential clinical variables that may cause poor mobilization (36-38). Over 347 the last 20 years, AMD3100 (Mozobil, Plerixafor) has been developed and is now the second FDA 348 approved mobilizing drug and is used, although at a significant increase in cost, as a second line 349 treatment for patients who have failed G-CSF plus chemotherapy mobilization (39). 350
To measure the mobilization of HSPCs in hBM-on-a-chip, we developed a protocol that allowed 351 for the periodic measurement of cell movement over a 24-hour period. We did so because we did 352 not anticipate HSPCs would be drawn out of the hBM-on-a-chip, because there was no 353 supplemented chemokine or existing gradient within the device that would direct the HSPCs in a 354 specific direction. Rather, we hypothesized that mobilization would disrupt local signaling that 355 was restricting HSPC movement and would therefore lead to an increase in either the magnitude or 356 displacement of migration during a given time period. 357
While the mechanism of mobilization by AMD3100 is specific, G-CSF mobilization likely occurs 358 through multiple pathways. G-CSF stimulates macrophages, osteoblasts, and osteoclasts to 359 upregulate proteases (MMP9, cathepsins, etc.) that subsequently degrade CXCL12 and surface 360 bound VLA-4 and CXCR4 on HSPCs (40-45). This disrupts the CXCL12-CXCR4 signaling axis 361 and leads to an increase of HSPCs in peripheral blood. Because G-CSF mobilization is indirect 362 and is mediated by stromal cells, onset of mobilization by G-CSF is relatively slow, taking more 363 than 24 hours to reach maximum mobilization (46). AMD3100 is an antagonist of CXCR4 and 364 directly competes with CXCL12 for binding. Consequently, AMD3100 mobilization is faster than 365 G-CSF, with HSPCs elevated in peripheral blood as early as 30 minutes post injection (47). When 366 used in combination with G-CSF, AMD3100 mobilizes more CD34+ HSPCs and has more 367 predictable kinetics than G-CSF alone (48-51). Currently preclinical mobilization studies are 368 restricted to animal models (52) and a sophisticated in vitro platform could be beneficial to screen 369 novel therapeutics on a large population of human samples or in a patient specific BM model to 370 assess an individual's mobilization potential. 371
Mobilizing the HSPCs with G-CSF, we observed a dose specific response that lead to increased 372 total length of migration and displacement over approximately a 14-hour period compared with the damage to all tissue types, the vasculature in BM is damaged and blood flow is disturbed (57). The 392 perivascular niche for HSPCs is likely damaged and recovery of this microenvironment is essential 393 for the regeneration of the hematopoietic system. The effects of radiation have, in the past, been 394 studied mostly in animal models, recently organ-on-chip systems have been explored for their 395 potential application in radiobiology (62, 63). Using organ-on-chip systems to examine the 396 biologically response to radiation exposure not only moves preclinical studies away from animal 397 models, but it may better recapitulate the response of human cells in radiation exposure situations. 398
Unexpectedly, exposure to relatively high doses of X-ray radiation (up to 10 Gy) did not induce a 399 significant increase in cell death in vascularized endosteal niche hBM-on-a-chip (EC+MSC+OB), 400
as measured by LDH release. There was a corresponding decrease, although not statistically 401 significant, in cytokine expression 24 hours after radiation exposure. This suggested that the 402 expression and, subsequently, the BM niche were potentially altered, albeit without widespread 403 apoptosis of stromal cells. HSPCs cultured in the vascularized endosteal niche 404 (HSPC+EC+MSC+OB) similarly did not exhibit a significant increase in apoptosis 24 hours after 405 exposure as measured by damage to nuclear DNA (TUNEL). In comparison, we observed an 406 increase, although not statistically significant, in TUNEL + HSPCs in the perivascular niche 407 (HSPC+EC+MSC) after 5 Gy radiation exposure. MSCs have been reported to be resistant to 408 damage associated with radiation exposure (56) and given the greater number of MSC derived 409 cells in OB containing devices, the density of these radio-resistant (and potentially radio 410 protective) cells could be mitigating damage to HSPCs. Further study measuring the production of 411 reactive oxygen species (ROS) after radiation exposure of the perivascular and vascularized 412 endosteal niches may help explain the difference in HSPC outcome in these microenvironments. 413
Materials and Methods
414
Device design and fabrication 415
Photomask (CAD/Art Services) was designed using AutoCAD software (Autodesk). An SU-8 416 master mold was fabricated using previously described soft lithography techniques.(64) Briefly, 417 SU-8 2150 (Microchem) was spun to a thickness of ~120 µm on a silicon wafer (University 418 Wafers) using a G3P8 Spin Coater (SCS). SU-8 was exposed with UV light through the 419 photomask using an MJB4 mask aligner (Suss Microtec). Uncrosslinked SU-8 was removed with 420 SU-8 developer (Microchem) and silicon wafers were treated by vapor phase deposition of 421 trichloro (1H, 1H, 2H, 2H-perfluorooctyl)silane (Sigma-Aldrich) to increase surface 422 hydrophobicity. 423
Polydimethylsiloxane (PDMS) (Dow Corning) was mixed 10:1 (elastomer base: curing agent) and 424 cast on silicone master mold. PDMS was cured at 65 ºC. The PDMS layer containing the features 425 was then removed from the master mold, a 3D printed reservoir mold was aligned on top and 426 additional PMDS (10:1) was poured on top of the device to form media reservoirs. After curing at 427 65 ºC, loading ports were made using 1 mm biopsy punch (Integra Miltex). Devices were bonded 428 to a thin film (~300 um) of PDMS (5:1) using a plasma cleaner (Harrick Plasma). Prior to use, 429 devices were washed with 70% EtOH. Aldrich) supplemented with 100 ng/mL SCF, TPO, and G-CSF (Peprotech). All cells were 445 cultured at 37 ºC and 5% CO 2 . 446
Osteogenesis in hBM-on-a-chip 447
For the formation of the endosteal niche, hMSCs were seeded within the central gel channels of 448 devices at a density of 5x10 5 cells/mL. Cells were cultured within the devices for 21 days in 449 MEM osteogenic media (10% FBS, 1% penicillin-streptomycin, 10 mM -glycerophosphate 450 (Sigma-Aldrich), 50 µM ascorbic acid (Sigma-Aldrich), and 100 nM dexamethasone (Sigma-451 Aldrich)) with daily media exchange. 452
Alizarin red and von Kossa staining 453
Osteogenic devices were washed with PBS, fixed with 4% formaldehyde in PBS for 15 von Kossa and Alizarin, respectively, to measure mean intensity and percent area. 464
Vasculogenesis in hBM-on-a-chip 465
Vasculogenesis in central gel channel was accomplished using previously reported approaches (33, 466 65). Briefly, HUVECs (12x10 6 cells/mL) and MSCs (6x10 5 cells/mL) were suspended in EBM-467 2MV supplemented with thrombin (4 U/mL) (Sigma-Aldrich). A solution of fibrinogen (8 mg/mL) 468 (Sigma-Aldrich) and collagen I (2 mg/mL) (Corning) in PBS was loaded into a central gel channel 469 reservoir. The HUVEC/MSC cell suspension was added to fibrinogen solution (1:1) and mixed 470 thoroughly. (Final cell suspension: HUVECs (6x10 6 cells/mL), hMSCs (3x10 5 cells/mL), thrombin 471
(2 U/mL), fibrinogen (4 mg/mL), collagen I (1 mg/mL)). Immediately, the hMSC/HUVEC cell 472 suspension was withdrawn from the opposite central gel port, drawing the cell suspension through 473 the central gel channel. Devices were then incubated for 15 minutes at 37 ºC, 5% CO 2 to allow the 474 fibrin gel to form. EBM-2MV was added to a reservoir on each side of gel channel and pulled 475 through media channel, into connecting reservoir by using a micropipette to create negative 476 pressure in the connecting 1-mm port. Cells were cultured with daily media exchange for 5 days to 477 allow for vasculogenesis. Media was supplemented with VEGF (50 ng/mL) on day 2 and with 478 VEGF (50 ng/mL) and angiopoietin-1 (ANG-1) (100 ng/mL) (Peprotech) on days 3, 4, and 5. 479
Immunofluorescence staining 480
Staining procedure for devices was adapted from Chen et al 2007 (27) . Devices were washed with 481 PBS, fixed with 4% formaldehyde (ThermoFisher), and permeabilized with 0.1% Triton X-100. 482
Prior to staining, cells were blocked with 5% BSA, 3% goat serum in PBS. Primary antibodies 483 Angiotool(66) to measure percent area and total network length. 495
Multiplex cytokine detection 496
Media was collected from devices at designated time by collecting media from one side of device, 497 waiting for 5 minutes to allow for gravity driven flow through the device and then collection of all 498 media from reservoirs. Device media was immediately stored on ice and then flash frozen in liquid 499 N 2 for storage prior to analysis. Samples were thawed on ice prior to detection and analysis using 500
LEGENDplex human hematopoietic stem cell panel (BioLegend), according to manufacturer's 501 protocol. 502 CD34+ HSPCs culture in hBM-on-a-chip 503 BM CD34+ HSPCs were labelled with PKH67 green fluorescent cell stain (Sigma-Aldrich) and 504 loaded at a final concentration of 3x10 5 (20:1 HUVEC:HSPC ratio, 6x10 5 HSPCs/mL in thrombin 505 cell suspension prior to mixing with fibrinogen). This concentration results in ~500 HSPCs within 506 the central channel. Devices were imaged on days 1, 3, and 5 after loading using a Lionheart FX 507 (BioTek Instruments). Images were analyzed using Gen5 (BioTek Instruments) to count the 508 number of HSPCs and progenitors at each time point. 509
Mobilization of HSPCs 510
After 5 days of culture, hBM-on-a-chips were imaged periodically to measure the "mobilization" 511 of CD34+ HSPCs. Baseline measurements were made at 0 hours, after which supernatants were 512 collected and was replaced with media supplemented with mobilizing agents at indicated 513 concentrations. Samples were imaged at intervals of 2 hours for 24 hours for a total of 13 image 514 sessions. During each image session, devices were imaged at intervals of 5 minutes for 15 minutes, 515 for a total of 4 time points. Samples were imaged using a Cytation 3 (BioTek Instruments) and 516 automated imaging of multiple plates was achieved using a BioSpa 3 (BioTek Instruments). Image 517 sequences were imported into Volocity software (PerkinElmer), cells were tracked within each 518 image session, and the length and displacement of individual cells were measured at each time 519 point. 520
Radiation exposure 521
On day 5, hBM-on-a-chip devices were transported to an animal facility and exposed to ionizing 522 radiation using an RS 2000 X-ray Irradiator (Rad Source). To control for effects of transportation, 523 untreated samples were also transported to the facility. The duration of the process (transportation 524 to and from the facility and X-ray exposure) was ~1 hour, during which time the samples were not 525 held at 37 °C, 5% CO 2 . 526 TUNEL assay 527 DNA damage to HSPCs was observed using terminal deoxynucleotidyl transferase-mediated 528 dUTP-biotin nick-end labelling (TUNEL) immunostaining (Click-iT TUNEL Alexa Fluor Assay 529 Kit, ThermoFisher) according to the manufacturer's protocol. Briefly, formaldehyde fixed devices 530 were first permeabilized with Triton-X100 (Avocado). Next, terminal deoxynucleotidyl transferase 531 (TdT) was used to incorporate dUTP into double stranded breaks of DNA. Alexa Fluor 647 azide 532 was then bound to dUTP using click chemistry. As membrane stains of HSPCs do not survive 533
Triton-X100 permeabilization, HSPCs were then stained overnight using anti-human CD45 Alexa 534
Fluor 488 (BioLegend). Samples were imaged using a spinning disk confocal microscope 535 (PerkinElmer) and images were analyzed using Volocity software (PerkinElmer). 536
Statistical analysis 537
Sample sizes are indicated in the figure captions and individual data points are shown. GraphPad 538
Prism was used for statistical analysis. Groups were tested for normality using the Shapiro 
